Episode 52
Biotech Hangout
00:00
The Impact of the IRA on Small Biotech Companies
The small molecule nine-year negotiation free period would be extended to match the biologics at 2013 so if anything they're going in the other direction. You know fundamentally though to me what this also says is that these negotiations aren't meant to be so draconian as to fundamentally generalize these drugs earlier. I think the US government ultimately wants to feel like they're getting good value for the money spend and find ways to contain costs. It's not clear you know who you know who's going to come to the rescue now of the industry.
Transcript
Play full episode
